Salbutamol

How to order Salbutamol

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Salbutamol on Prescriptsy

Salbutamol is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Salbutamol is a short-acting beta2-agonist (SABA) bronchodilator that provides rapid relief of acute bronchospasm in asthma, chronic obstructive pulmonary disease (COPD), and other conditions involving reversible airway obstruction.

It is the most widely prescribed reliever inhaler in the United Kingdom and the first-line rescue treatment recommended by NICE, BTS/SIGN, and GINA guidelines.

Salbutamol is available as a pressurised metered-dose inhaler (pMDI), dry powder inhaler, nebuliser solution, and oral preparations. Well-known UK brand names include Ventolin, Salamol, and Airomir.

This page provides a comprehensive clinical guide to salbutamol, covering how it works, correct dosage, side effects, important safety warnings, and how to obtain a prescription in the United Kingdom.

Important safety information about salbutamol

• Salbutamol is a reliever inhaler. It treats symptoms but does not control the underlying inflammation in asthma. If you have asthma, you should also use an inhaled corticosteroid (ICS) preventer as prescribed.
• If you need your salbutamol inhaler three or more times per week, your asthma may not be well controlled. Book an urgent review with your GP or asthma nurse.
• Over-reliance on salbutamol without adequate preventer treatment is associated with increased risk of severe asthma attacks and death.
• Always carry your salbutamol inhaler. In an asthma emergency, take one puff every 30 to 60 seconds up to 10 puffs, then call 999 if not improving.
• Salbutamol is safe during pregnancy and breastfeeding. Do not stop your asthma treatment without medical advice.

Understanding asthma and the role of reliever inhalers

Asthma is a chronic inflammatory condition of the airways affecting approximately 5.4 million people in the United Kingdom, including 1.1 million children.

The hallmarks of asthma are variable airflow obstruction, airway hyperresponsiveness, and chronic airway inflammation.

Symptoms include wheeze, breathlessness, chest tightness, and cough, which are typically worse at night or early morning and triggered by exercise, cold air, allergens, or respiratory infections.

Asthma management follows a stepwise approach as outlined in NICE guideline NG80 and BTS/SIGN guideline SIGN 158, with a SABA reliever inhaler (salbutamol) available at every step for rapid symptom relief.

Chronic obstructive pulmonary disease is another major cause of airflow obstruction, primarily affecting smokers and former smokers over the age of 35.

COPD is characterised by persistent airflow limitation that is not fully reversible.

Salbutamol is used as a reliever in COPD, though long-acting bronchodilators (LABAs and LAMAs) are the mainstay of maintenance therapy.

NICE guideline NG115 outlines the management of COPD in the UK.

How salbutamol works

Salbutamol is a selective beta2-adrenoceptor agonist. Beta2-receptors are found in high density on airway smooth muscle cells.

When salbutamol binds to these receptors, it activates the enzyme adenylyl cyclase via a stimulatory G-protein (Gs).

Adenylyl cyclase catalyses the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP).

Elevated intracellular cAMP levels activate protein kinase A (PKA), which phosphorylates myosin light chain kinase, reducing its activity and causing relaxation of airway smooth muscle.

This produces bronchodilation, opening the narrowed airways and allowing air to flow more freely.

Beyond bronchodilation, salbutamol has several additional pharmacological effects that contribute to symptom relief.

It stabilises mast cells and inhibits the release of bronchoconstrictor mediators such as histamine and leukotrienes. It reduces microvascular leakage in the airway mucosa, which helps decrease oedema.

It enhances mucociliary clearance, assisting the removal of mucus from the airways. These effects, combined with rapid bronchodilation, make salbutamol an effective rescue treatment during acute bronchospasm.

The onset of action of inhaled salbutamol is typically within 3 to 5 minutes, with peak bronchodilator effect at 15 to 30 minutes.

The duration of action is approximately 4 to 6 hours.

This rapid onset distinguishes salbutamol from long-acting bronchodilators such as salmeterol and formoterol, which are designed for maintenance therapy rather than acute relief.

Why salbutamol alone is not enough for asthma

While salbutamol is highly effective at relieving bronchospasm, it does not address the chronic airway inflammation that drives asthma.

Airway inflammation involves infiltration of eosinophils, mast cells, T-lymphocytes, and other inflammatory cells into the bronchial mucosa, with associated structural changes (airway remodelling) including subepithelial fibrosis, goblet cell hyperplasia, and smooth muscle hypertrophy.

Without anti-inflammatory treatment, this process continues and worsens over time, leading to progressively more frequent and severe symptoms.

The National Review of Asthma Deaths (NRAD, 2014) examined 195 asthma deaths in the UK and found a consistent pattern of over-reliance on reliever inhalers and inadequate use of preventer inhalers.

Forty-six per cent of those who died had been prescribed 12 or more SABA inhalers in the year before death, suggesting severe over-reliance on reliever therapy.

The review recommended that any patient prescribed more than 3 SABA inhalers per year should have their asthma management reviewed.

This finding is reflected in NICE quality standard QS25 and the NICE guideline NG80 recommendation that SABA use should trigger a review of preventer therapy.

For most people with asthma, treatment begins at step 1 with a SABA reliever and a low-dose ICS preventer.

The ICS reduces airway inflammation, prevents symptoms, and reduces the risk of exacerbations. Higher steps add additional controllers such as LABAs, leukotriene receptor antagonists, or increased ICS doses.

The key principle is that the ICS preventer controls the disease, while salbutamol provides rapid relief of breakthrough symptoms.

Clinical evidence for salbutamol

Salbutamol was first introduced in the late 1960s by Allen and Hanburys (now part of GSK) and was the first selective beta2-agonist developed for clinical use.

It represented a significant advance over earlier non-selective sympathomimetics such as isoprenaline, which stimulated both beta1 (cardiac) and beta2 (bronchial) receptors and caused significant cardiac side effects.

Salbutamol's selectivity for beta2-receptors gave it a substantially improved safety profile.

Decades of clinical use and hundreds of clinical trials have established salbutamol as the standard first-line reliever for asthma and acute bronchospasm.

Systematic reviews confirm its efficacy in rapidly improving FEV1 (forced expiratory volume in one second), reducing symptoms, and improving quality of life in both asthma and COPD.

In acute asthma, nebulised salbutamol remains the cornerstone of emergency treatment alongside systemic corticosteroids and oxygen therapy, as outlined in BTS/SIGN guideline SIGN 158 and NICE guideline NG80.

Salbutamol formulations available in the UK

The most common formulation is the pressurised metered-dose inhaler (pMDI), which delivers 100 micrograms per actuation.

UK brands include Ventolin Evohaler, Salamol Easi-Breathe (a breath-actuated pMDI that removes the need for coordination), and Airomir Autohaler.

Dry powder inhalers include the Ventolin Accuhaler (delivering 200 micrograms per blister). Nebuliser solutions are available in 2.5 mg and 5 mg unit doses (Ventolin Nebules).

Oral salbutamol (tablets and syrup) is available but rarely used due to greater systemic side effects and slower onset compared with inhaled formulations.

The choice of inhaler device should be based on the patient's ability to use it correctly.

Inhaler technique is frequently suboptimal, and incorrect technique significantly reduces drug delivery to the lungs. Pharmacists can check and demonstrate inhaler technique.

The Asthma and Lung UK charity provides online videos and resources to help patients learn correct technique for different devices.

How to use a salbutamol pMDI

Remove the mouthpiece cap. Shake the inhaler well. Hold the inhaler upright with your thumb on the base and your index finger on the canister.

Breathe out gently away from the inhaler. Place the mouthpiece between your lips and form a seal.

Begin to breathe in slowly and deeply through your mouth, and at the same time press the canister down once to release one puff.

Continue to breathe in slowly and deeply.

Remove the inhaler from your mouth and hold your breath for approximately 10 seconds, or as long as is comfortable, then breathe out gently.

If a second puff is needed, wait 30 to 60 seconds before repeating.

Using a spacer device (such as an AeroChamber Plus or Volumatic) with a pMDI significantly improves drug delivery to the lungs, particularly for patients who find it difficult to coordinate pressing the canister and breathing in simultaneously.

The spacer allows the aerosol particles to decelerate, reducing oropharyngeal deposition and increasing the fine particle fraction that reaches the lower airways.

Spacers are recommended for all children and for any adult who has difficulty with standard pMDI technique.

Dosage and administration

For adults and adolescents aged 12 and over: 100 to 200 micrograms (one or two puffs) as needed for symptom relief, up to four times daily.

In acute exacerbations, higher doses may be used under medical supervision. For children aged 4 to 11: 100 to 200 micrograms as needed.

For children under 4: 100 micrograms via pMDI with spacer and face mask, repeated as required under medical supervision.

For nebulisation in acute severe asthma in adults: 2.5 to 5 mg via nebuliser driven by oxygen. This may be repeated every 15 to 30 minutes.

In life-threatening asthma, continuous nebulisation with 5 to 10 mg per hour may be used. In children, nebulised doses are adjusted by weight and severity.

These doses are administered in hospital or by ambulance paramedics.

For prevention of exercise-induced bronchospasm: 200 micrograms (two puffs) taken 10 to 15 minutes before exercise.

Side effects of salbutamol

Common side effects

Tremor is the most frequently reported side effect, affecting up to 10% of users.

It is a fine tremor affecting the hands and is caused by beta2-receptor stimulation of skeletal muscle. It is usually mild and diminishes with regular use.

Headache is also common. Palpitations and a transient increase in heart rate may occur but are usually not clinically significant at standard inhaled doses.

Uncommon side effects

Muscle cramps may occur, particularly in the legs. These may be related to mild hypokalaemia caused by beta2-agonist-mediated intracellular potassium shift. Mouth and throat irritation is reported by some users. Hyperactivity and behavioural changes may occur in children.

Serious side effects

Hypokalaemia is a potentially serious effect at high doses, particularly when salbutamol is given by nebuliser in combination with other medicines that lower potassium (theophylline, systemic corticosteroids, diuretics).

Severe hypokalaemia can cause cardiac arrhythmias. Serum potassium should be monitored during high-dose nebulised salbutamol therapy in hospital settings.

Paradoxical bronchospasm (worsening wheeze or breathlessness immediately after inhalation) is rare. If this occurs, stop using the inhaler, use an alternative reliever or nebuliser, and seek immediate medical attention.

Lactic acidosis has been reported rarely with high-dose intravenous or nebulised salbutamol, manifesting as unexplained metabolic acidosis with elevated lactate levels.

When to seek urgent medical attention

Call 999 or attend A and E if you experience severe chest pain, sustained rapid or irregular heartbeat, severe breathing difficulty unresponsive to salbutamol, or signs of a severe allergic reaction (swelling of the face, lips, or throat, widespread rash, difficulty breathing).

Call NHS 111 for advice on non-urgent side effects. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Over-reliance on reliever inhalers

The single most important safety message regarding salbutamol is that it must not be used as a substitute for regular preventer therapy in asthma.

If you are using your salbutamol inhaler three or more times per week (excluding use before exercise), this indicates poorly controlled asthma and you should see your GP or asthma nurse promptly.

The NRAD report and subsequent NICE quality standards have highlighted the association between excessive SABA use and poor asthma outcomes, including death.

Drug interactions

Non-selective beta-blockers (such as propranolol) are contraindicated in patients with asthma because they block beta2-receptors and may precipitate severe bronchospasm.

Cardioselective beta-blockers (such as bisoprolol and atenolol) are less likely to cause this effect but should still be used with caution.

Beta-blocker eye drops (timolol) can also trigger bronchospasm in susceptible patients.

Potassium-depleting medicines (loop and thiazide diuretics, corticosteroids, theophylline) may increase the risk of hypokalaemia when combined with high-dose salbutamol.

Special populations

Pregnancy and breastfeeding: salbutamol has been used extensively during pregnancy. There is no evidence of harm to the developing baby.

Uncontrolled asthma during pregnancy is associated with pre-eclampsia, preterm birth, and low birth weight, which carry greater risk than the use of salbutamol.

Salbutamol is considered compatible with breastfeeding.

Elderly patients: standard doses apply. Monitor for cardiovascular effects, particularly in patients with pre-existing cardiac conditions.

Children: salbutamol may be used from infancy. Appropriate device selection (pMDI with spacer and face mask for children under 4) and inhaler technique training are essential.

How to get salbutamol in the UK

Salbutamol is available on NHS prescription from your GP, asthma nurse, or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Some pharmacies may supply salbutamol under a patient group direction (PGD) to patients with an existing asthma diagnosis who have been previously prescribed salbutamol.

Prepayment certificates are available for those needing multiple prescriptions.

Sources

• Ventolin Evohaler, Summary of Product Characteristics (EMC)
• Salbutamol, British National Formulary (BNF)
• Asthma: diagnosis, monitoring and chronic asthma management, NICE NG80
• BTS/SIGN guideline SIGN 158 on asthma management
• Salbutamol inhaler, NHS
• MHRA Yellow Card Scheme